Two Seas Capital LP Increases Stock Holdings in Immunovant, Inc. $IMVT

Posted by Brenda Bartman on Jun 6th, 2026

Two Seas Capital LP boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 3.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,866,962 shares of the company’s stock after acquiring an additional 104,922 shares during the quarter. Immunovant accounts for 1.5% of Two Seas Capital LP’s portfolio, making the stock its 10th biggest holding. Two Seas Capital LP’s holdings in Immunovant were worth $72,878,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IMVT. Deep Track Capital LP increased its position in Immunovant by 2.4% in the third quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock worth $156,829,000 after buying an additional 228,845 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Immunovant by 14.0% in the fourth quarter. Vanguard Group Inc. now owns 7,779,314 shares of the company’s stock worth $197,750,000 after acquiring an additional 952,504 shares during the period. Armistice Capital LLC boosted its stake in shares of Immunovant by 12.2% in the third quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock worth $94,076,000 after acquiring an additional 636,000 shares during the period. Alpine Global Management LLC boosted its stake in shares of Immunovant by 4.9% in the third quarter. Alpine Global Management LLC now owns 2,754,731 shares of the company’s stock worth $44,406,000 after acquiring an additional 128,039 shares during the period. Finally, ADAR1 Capital Management LLC boosted its stake in shares of Immunovant by 319.0% in the third quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock worth $36,137,000 after acquiring an additional 1,706,687 shares during the period. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Analyst Ratings Changes

IMVT has been the subject of a number of recent analyst reports. Citigroup reaffirmed a “buy” rating on shares of Immunovant in a research note on Thursday, May 21st. Truist Financial increased their price target on Immunovant from $23.00 to $30.00 and gave the company a “hold” rating in a research note on Friday, May 22nd. Sanford C. Bernstein started coverage on Immunovant in a research note on Friday, March 20th. They set a “market perform” rating and a $28.00 price target for the company. HC Wainwright increased their price target on Immunovant from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunovant in a research note on Wednesday, April 8th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $37.33.

View Our Latest Stock Report on IMVT

Insiders Place Their Bets

In other news, CTO Jay S. Stout sold 2,754 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $29.62, for a total value of $81,573.48. Following the completion of the sale, the chief technology officer directly owned 251,685 shares of the company’s stock, valued at $7,454,909.70. This trade represents a 1.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Andrew J. Fromkin sold 221,951 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $33.51, for a total value of $7,437,578.01. Following the completion of the sale, the director directly owned 74,382 shares of the company’s stock, valued at $2,492,540.82. The trade was a 74.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 300,092 shares of company stock worth $9,553,291. 1.80% of the stock is currently owned by company insiders.

Immunovant Price Performance

NASDAQ:IMVT opened at $31.11 on Friday. The firm has a market capitalization of $6.39 billion, a price-to-earnings ratio of -11.19 and a beta of 0.76. Immunovant, Inc. has a 1 year low of $14.32 and a 1 year high of $36.28. The business has a 50 day simple moving average of $28.50 and a 200-day simple moving average of $26.55.

Immunovant (NASDAQ:IMVT – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.13). During the same quarter last year, the company earned ($0.64) earnings per share. As a group, analysts expect that Immunovant, Inc. will post -2.65 earnings per share for the current fiscal year.

About Immunovant

(Free Report)

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.